ArticleAbdominal radiology (New York)2025
Efficacy and safety of renal artery embolization for blunt traumatic renal hemorrhage: a multicenter study.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of renal artery embolization (RAE) for the management of blunt traumatic renal hemorrhage.
methodsPatients with blunt traumatic renal hemorrhage treated with RAE across four hospitals from January 2018 to December 2024 were included in the study. Technical and clinical success rates, renal function preservation, side effects and complication were analyzed.
resultsIn the 71 study patients, the technical success rate of RAE was 100%, and the clinical success rate was 93.0% (66/71). The mean RAE procedure time was 1.2 ± 0.5 h and which was increased with higher American Association for the Surgery of Trauma (AAST) grades, and significantly longer was required for higher AAST grade. The mean infarcted renal area was 38% (range, 15-80%). The average serum creatinine level pre- and 1, 3, 5 and 7 days post-RAE were 95.6 ± 47.1 µmol/L, 99.0 ± 44.3 µmol/L, 88.4 ± 31.7 µmol/L, 85.0 ± 27.5 µmol/L and 78.5 ± 41.1 µmol/L, respectively. Different embolic materials (coils vs. gelatin sponge particles) showed no significant differences in technical and clinical success rates but highlighted cost advantages for gelatin sponge particles (4003.4 ± 1381.9 vs. 1919.4 ± 345.7 CNY; P < 0.001). The most common side effect was fever (42.3%), while no RAE related major complications.
conclusionRAE is a highly effective and minimally invasive treatment for blunt traumatic renal hemorrhage, with significant success in hemostasis and renal function preservation. Gelatin sponge particles should be used as first line choice for RAE.
Indexed as
Identifiers
40304750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.